Abstract
Aims: Pleomorphic lobular carcinoma in situ (PLCIS) of the breast is a distinctive entity, but its behaviour and management are unclear. The purpose of this study was to review a relatively large number of cases and to evaluate the risk of recurrence. Methods and results: Cases of PLCIS (n = 47) from a 12-year period were reviewed. The clinical, radiological and pathological findings were recorded. Immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR) and HER2 was performed. Thirty-one patients had no concurrent breast cancer or past history of breast cancer, and six (19.4%) of these had local recurrence; all tumours (four invasive carcinoma and two PLCIS) were ipsilateral. Younger age at presentation was a risk factor for local recurrence: patients with recurrence had a mean age (range) of 52.5 years (44-59 years), versus 60.6 years (40-81 years) for those without (P = 0.03). Three of 31 patients were treated with radiation therapy (RT), and none of these developed local recurrence. PLCIS had an adverse ER/PR/HER2 molecular profile, with at least 41.2% of the cases overexpressing HER2. Moreover, at least 11.7% of the cases were triple-negative. Conclusions: This study included the largest number of patients who had no concurrent breast cancer or past history of breast cancer with the longest clinical follow-up, providing insights into management practices for PLCIS and the risk of recurrence.
Original language | English (US) |
---|---|
Pages (from-to) | 981-993 |
Number of pages | 13 |
Journal | Histopathology |
Volume | 64 |
Issue number | 7 |
DOIs | |
State | Published - Jun 2014 |
Keywords
- Adjuvant therapy
- Breast
- Local recurrence
- Pleomorphic lobular carcinoma in situ
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Histology